FindTrial
Sign In

Research on the diagnostic efficacy of calcitriol inhibition test for hyperparathyroidism

Research on the diagnostic efficacy of calcitriol inhibition test for hyperparathyroidism

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500115447
Enrollment
Unknown
Registered
2025-12-26
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic bone disease

Interventions

Calcitriol intervention group:Calcitriol 0.25ug tid*3 days will be administered
After the calcitriol inhibition test was completed, vitamin D supplementation was given ( - vitamin D3 5000IU once a day
- Continuous supplementation until 25OHD reaches 30-50ng/ml).

Sponsors

Department of Endocrinology and Metabolism, West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Elevated PTH (> upper limit of the reference range). - Insufficient or deficient 25OHD (<30ng/ml). - Normal blood calcium (2.1-2.52 mmol/L).

Exclusion criteria

Exclusion criteria: - Secondary hyperparathyroidism due to known primary or other causes such as renal insufficiency. - Other endocrine diseases affect calcium and phosphorus metabolism. - Pregnant or lactating women. - Severe liver and kidney dysfunction.

Design outcomes

Primary

MeasureTime frame
Serum calcium;PTH;—

Secondary

MeasureTime frame
Serum phosphorus;Serum albumin;25OHD;—

Countries

China

Contacts

Public ContactQin Wang

Department of Endocrinology and Metabolism, West China Hospital, Sichuan University

wangqin@wchscu.cn+86 189 8060 6561

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026